A newly devised flow cytometric antibody binding assay helps evaluation of dithiothreitol treatment for the inactivation of CD38 on red blood cells.
Hiroaki FurumakiAkihiro TakeshitaHitoshi OhtoChiaki YamadaHarumi FujiharaKeiko IshizukaHiroki ShibataTakahito ShinbaNaoki NemotoKaede InoAkari OzawaHiroko WatanabeKinuyo KawabataYukako ObataPublished in: Vox sanguinis (2020)
Flow cytometric antibody binding assay is an objective way of evaluating the efficacy of DTT treatment for CD38 on RBCs. This approach allows the detection of a small number of cell surface antigens and will be useful for assessing the various chemical treatments to denature RBC antigens.